The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Molecular Profiling Refines Salivary Gland Tumor Diagnosis
Molecular profiling improves the diagnostic accuracy and identification of actionable alterations in complex salivary gland tumors, complementing traditional histopathology.
Jideytro offers new hope for ROS1-positive NSCLC after prior therapy
The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, providing a new option for this rare subtype.
Forget sterile tumors: Cancers house unique microbiomes
A comprehensive analysis of over 17,000 tumor samples confirms distinct microbial signatures across 35 cancer types, influencing prognosis and treatment response.
Lung Transplants Extend Survival for Select Stage 4 Cancer Patients
South African Scientists Decipher Cancer's Survival Strategy
Sitting for Long Stretches Linked to Higher Cancer Mortality Risk
Cancer survival improves. Why are rural outcomes still worsening?
How non-animal models are redefining oncology drug safety
Men Face Later Cancer Diagnoses Across 20 Types
Liver Transplant Studies Retracted Over Organ Harvesting Concerns
Multiple liver transplant studies have been retracted from major medical journals due to concerns over the ethical sourcing of donor organs, raising serious questions about research integrity.
Chronic Hepatitis Delta Virus: Why direct viral targeting matters now
The FDA has approved the first treatment for chronic hepatitis delta virus (HDV) infection, addressing a severe form of viral hepatitis with high mortality.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Why cardiac amyloidosis diagnoses are surging and what it means for GPs
Cardiac amyloidosis diagnoses are increasing due to improved awareness and advanced imaging, revealing a previously underrecognized cause of heart failure.
Vapes and Snus: What the ESC Says About Cardiovascular Risk
The European Society of Cardiology has clarified its position on electronic cigarettes and snus, outlining distinct cardiovascular risks.
Smartphones and Pacemakers: Separating Fact from Electromagnetic Fiction
Modern smartphones pose minimal risk of electromagnetic interference with pacemakers and ICDs, provided a safe distance is maintained.
Pulsed Field Ablation: A New Frontier for Atrial Fibrillation?
Cardiovascular risk: Why men die earlier, women live sicker
For atrial fibrillation, integrated pathways may beat individual fixes
Severe VT in ischaemic cardiomyopathy: Why current care isn't enough
AI in the ED: Can algorithms truly accelerate acute cardiac care?
AFib ablation: Stop assuming success based on AFib type alone
Why lifestyle advice alone still dominates obesity searches
Despite advances in pharmacotherapy, Google searches for obesity management remain heavily skewed towards lifestyle interventions, indicating a persistent public perception.
Tzield expands its reach: A new option for recently diagnosed pediatric type 1 diabetes
The FDA approved Tzield (teplizumab) for pediatric patients with recently diagnosed Stage 3 type 1 diabetes, marking an expansion of its indication.
Pediatric CGM OTC: how will you counsel families?
The FDA has cleared the first over-the-counter continuous glucose monitor for children, expanding access to real-time glucose data for pediatric diabetes management.
Haaland's 6,000-Calorie Diet: Performance Fuel or Health Risk?
Metabolic Syndrome: Is it accelerating your patients' brain aging?
Targeted Therapy Reverses Weight Gain From Rare Cause of Obesity
Online GLP-1 Prescriptions Often Lack Clinical Oversight
Weight-Loss Jabs May Create a New Kind of Yo-Yo Dieting
Obesity as Disease: Who Benefits from the Redefinition?
Chronic Migraine: Is the Gut-Brain Axis the Missing Link?
Chronic migraine frequently co-occurs with gastrointestinal issues, suggesting a gut-brain axis involvement through dysbiosis and inflammation.
Cognitive Rehabilitation Eases Long-COVID Brain Fog
Cognitive rehabilitation significantly improved brain fog symptoms in patients with long-COVID, offering a structured approach to managing persistent neurological sequelae.
Football Headers Linked to Cognitive Decline, Neurodegeneration
Repeated head impacts from football headers correlate with increased risk of cognitive impairment and neurodegenerative disease, particularly in former professional players.
TBI Linked Bidirectionally With Psychiatric and Neurologic Conditions
Roche Halts Huntington's Gene-Silencing Programs
Dopamine Agonists: A Fading Role in Parkinson's Treatment?
Eptinezumab Improves Cognitive Symptoms in Migraine Patients
Creatine Supplementation: Limited Evidence for Brain Health Benefits
Migraine Linked to Increased Vascular Dementia Odds in Observational Data
Multiple MyelomaGene therapy for sickle cell: how young is too young for a functional cure?
Get the full story7 min readMAHA Monday: The Rush to Publish and Its Clinical Fallout
Get the full story11 min readLiso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment
Get the full story11 min readNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full story7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full story8 min readMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
Get the full story7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Get the full story8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Get the full story7 min readMacrophages: Dual Role in Haematological Malignancies Explored
Get the full story7 min read
Arthritis PsoriaticMissing early psoriatic arthritis means irreversible joint damage
Get the full story12 min readFrailty, not just RA, predicts osteoporotic fracture risk
Get the full story6 min readEnpatoran gets breakthrough tag for lupus: Another IFN-I inhibitor enters the fray
Get the full story7 min readMicrobiome's Role in Lupus: A Policy and Therapeutic 'Frame Shift'
Get the full story10 min readSleep Disruption and Fear Drive Chronic Rheumatic Pain
Get the full story11 min readWhy Cheaper Humira Alternatives Face Resistance
Listen now22 minStopping Spinal Fusion Or Protecting The Gut?
Listen now23 minChasing Absolute Zero In Rheumatoid Arthritis
Listen now21 minThe ORAL Surveillance JAK Inhibitor Controversy
Listen now21 minB-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
Get the full story7 min read
PneumoniaAir Embolism: Two Cases After Percutaneous Lung Biopsy
Get the full story7 min readSingle Question May Flag Poor Quality Sleep in Patients
Get the full story9 min readPembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC
Get the full story8 min readDupilumab Superior to Omalizumab in High-Biomarker Asthma
Get the full story7 min readATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
Get the full story8 min readBRINSUPRI® First Therapy Approved for NCFB at ATS 2026
Get the full story7 min readEpithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Get the full story8 min readTriple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Get the full story7 min readYUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
Get the full story8 min readIPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
Get the full story8 min read
Clostridioides difficileInfluenza treatment: The single-dose option challenges multi-day adherence
Get the full story7 min readScrewworm EUA: How targeting larval development changes prevention
Get the full story7 min readTreating screwworm: Why an OTC generic is now the frontline
Get the full story6 min readThe antibiotic paradox: More drugs won't solve resistance
Get the full story10 min readMeningitis B: Why campus life shifts vaccine guidance for your patients
Get the full story6 min readBlack Death Survivors' Genetic Legacy Offers Clues for COVID-19 Resilience
Get the full story10 min readLong COVID: Objective Biomarkers Challenge Psychosomatic Narrative
Get the full story8 min readNew Virus Catalogue Identifies Top Pathogen Threats to Human Health
Get the full story7 min readSodium Fluoroacetate Offers Hope Against Australia's Mouse Plagues
Get the full story7 min readHPV Vaccine Efficacy Hinges on Sustained Trust and Uptake
Get the full story11 min read
Dermatitis AtopicNew UV filters' secret: Photostability and broad-spectrum action
Get the full story7 min readPeptide Therapies: Decoding Evidence from Topicals to Longevity
Get the full story9 min readFDA Rejects Galderma's RelabotulinumtoxinA for Second Time
Get the full story7 min readCAR T-Cell Therapy Nears Approval for Refractory Skin Diseases
Get the full story7 min readTSW Controversy: Mitochondrial NAD Excess Identified, Diagnostic Clarity Emerges
Get the full story9 min readPrior Authorization Delays Atopic Dermatitis Treatment Access
Get the full story13 min readPatient-Reported Factors Redefine Alopecia Areata Severity
Get the full story8 min readScalp Lesions: Rare Malignancies Mimic Benign Conditions
Get the full story7 min readDown Syndrome: Skin Conditions Demand Dermatologists’ Attention
Get the full story8 min readGLP-1 Receptor Agonists and Psoriatic Disease: A Deep Dive
Get the full story8 min read
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30MunichAug 28 – 31 2026
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?
GLP-1 receptor agonists reduce cardiovascular risk in obese individuals with established CVD, but their benefit in primary prevention remains unclear.
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?
Factor XIa inhibitors offer a novel antithrombotic strategy after myocardial infarction, aiming for reduced bleeding risk compared to current agents.
Eplontersen: Can a new RNAi therapy change ATTR-CM outcomes?
Eplontersen significantly reduced transthyretin protein levels and improved clinical endpoints in ATTR amyloid cardiomyopathy.
Aficamten: A New Path for Non-Obstructive Hypertrophic Cardiomyopathy?
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition with limited treatment options. The drug targets cardiac myosin, reducing contractility and improving symptoms.
Ruling Out Heart Attacks Faster: The PRESC1SE-MI Study's ED Impact
The PRESC1SE-MI study demonstrated a novel algorithm using high-sensitivity troponin I can safely rule out myocardial infarction in the emergency department within one hour.
Do Statins Still Benefit Patients Over 70 Without Prior CVD?
The STAREE trial investigated statin use for primary prevention in individuals over 70, challenging long-held assumptions about cardiovascular benefit in this age group.
Why Transthyretin Amyloid Cardiomyopathy Remains Underdiagnosed
Transthyretin amyloid cardiomyopathy (ATTR-CM) often presents with non-specific symptoms, leading to significant diagnostic delays and missed opportunities for early intervention.
Can Factor XIa Inhibitors Reduce Post-MI Bleeding Without Compromising Efficacy?
Factor XIa inhibitors aim to reduce thrombotic events in acute coronary syndrome patients while minimizing bleeding risk, a critical balance in post-MI care.
Faster Heart Attack Rule-Out: Can PRESC1SE-MI Deliver on ED Efficiency?
A new strategy for ruling out myocardial infarction in emergency departments, using high-sensitivity troponin and clinical risk scores, demonstrated high safety and reduced length of stay.
Do Statins Prevent Dementia in Healthy Older Adults? STAREE Trial Weighs In
The STAREE trial investigated statin use in healthy adults over 70, finding no reduction in dementia incidence but a modest cardiovascular benefit.
Aficamten targets non-obstructive HCM, a disease with no approved drug
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition lacking specific approved therapies.
ESC Congress 2026: The 59 Pivotal Trials You Need to Know
Fifty-nine pivotal trials will present at ESC Congress 2026, covering major cardiovascular disease areas from heart failure to arrhythmia.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
Elevated lipoprotein(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease. Early identification and management are critical.
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?
GLP-1 receptor agonists reduce cardiovascular risk in obese individuals with established CVD, but their benefit in primary prevention remains unclear.
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?
Factor XIa inhibitors offer a novel antithrombotic strategy after myocardial infarction, aiming for reduced bleeding risk compared to current agents.
Eplontersen: Can a new RNAi therapy change ATTR-CM outcomes?
Eplontersen significantly reduced transthyretin protein levels and improved clinical endpoints in ATTR amyloid cardiomyopathy.
Aficamten: A New Path for Non-Obstructive Hypertrophic Cardiomyopathy?
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition with limited treatment options. The drug targets cardiac myosin, reducing contractility and improving symptoms.
Ruling Out Heart Attacks Faster: The PRESC1SE-MI Study's ED Impact
The PRESC1SE-MI study demonstrated a novel algorithm using high-sensitivity troponin I can safely rule out myocardial infarction in the emergency department within one hour.
Do Statins Still Benefit Patients Over 70 Without Prior CVD?
The STAREE trial investigated statin use for primary prevention in individuals over 70, challenging long-held assumptions about cardiovascular benefit in this age group.
Why Transthyretin Amyloid Cardiomyopathy Remains Underdiagnosed
Transthyretin amyloid cardiomyopathy (ATTR-CM) often presents with non-specific symptoms, leading to significant diagnostic delays and missed opportunities for early intervention.
Can Factor XIa Inhibitors Reduce Post-MI Bleeding Without Compromising Efficacy?
Factor XIa inhibitors aim to reduce thrombotic events in acute coronary syndrome patients while minimizing bleeding risk, a critical balance in post-MI care.
Faster Heart Attack Rule-Out: Can PRESC1SE-MI Deliver on ED Efficiency?
A new strategy for ruling out myocardial infarction in emergency departments, using high-sensitivity troponin and clinical risk scores, demonstrated high safety and reduced length of stay.
Do Statins Prevent Dementia in Healthy Older Adults? STAREE Trial Weighs In
The STAREE trial investigated statin use in healthy adults over 70, finding no reduction in dementia incidence but a modest cardiovascular benefit.
Aficamten targets non-obstructive HCM, a disease with no approved drug
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition lacking specific approved therapies.
ESC Congress 2026: The 59 Pivotal Trials You Need to Know
Fifty-nine pivotal trials will present at ESC Congress 2026, covering major cardiovascular disease areas from heart failure to arrhythmia.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
Elevated lipoprotein(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease. Early identification and management are critical.
